Unconventional Remedies for Squamous Cell Carcinoma: A Journey into Alternative Treatments


Cite item

Full Text

Abstract

:Squamous cell carcinoma (SCC) is the second most common form of skin cancer and is typically found on sun-exposed skin. Risk factors include ultraviolet radiation exposure, older age, fairer complexion, smoking, and immunosuppression. SCC is a slow-growing tumor with the possibility of metastasis if not treated. The clinical presentation can range from a dry, scaly erythematous patch or plaque to a firm hyperkeratotic papule, plaque, or nodule, depending on the histological type via biopsy. The first-line therapies for SCC removal are standard excision and Mohs microscopic surgery; however, there are novel and alternative non-surgical options being considered for the treatment of SCC. This review summarizes the current guidelines for treating low-risk and high-risk SCC and discusses rare, experimental, and anecdotal non-surgical treatments for SCC in the literature.

About the authors

Elen Deng

, Penn State College of Medicine

Email: info@benthamscience.net

Amor Khachemoune

Department of Dermatology, SUNY Downstate

Author for correspondence.
Email: info@benthamscience.net

References

  1. Fania, L.; Didona, D.; Di Pietro, F.R. Cutaneous squamous cell carcinoma: From pathophysiology to novel therapeutic approaches. Biomedicines, 2021, 9(2), 171. doi: 10.3390/biomedicines9020171
  2. Howell, J.Y.; Ramsey, M.L. Squamous cell skin cancer. In: StatPearls; StatPearls Publishing: Treasure Island, FL, 2023.
  3. Yanofsky, V.R.; Mercer, S.E.; Phelps, R.G. Histopathological variants of cutaneous squamous cell carcinoma: A review. J. Skin Cancer, 2011, 2011, 1-13. doi: 10.1155/2011/210813 PMID: 21234325
  4. Lin, J.L.; Asgari, M. Cutaneous squamous cell carcinoma (cSCC): Clinical features and diagnosis. Available from: https://www.uptodate.com/contents/cutaneous-squamous-cell-carcinoma-cscc-clinical-features-and-diagnosis#
  5. Kim, J.Y.S.; Kozlow, J.H.; Mittal, B.; Moyer, J.; Olenecki, T.; Rodgers, P.; Alam, M.; Armstrong, A.; Baum, C.; Bordeaux, J.S.; Brown, M.; Busam, K.J.; Eisen, D.B.; Iyengar, V.; Lober, C.; Margolis, D.J.; Messina, J.; Miller, A.; Miller, S.; Mostow, E.; Mowad, C.; Nehal, K.; Schmitt-Burr, K.; Sekulic, A.; Storrs, P.; Teng, J.; Yu, S.; Huang, C.; Boyer, K.; Begolka, W.S.; Bichakjian, C. Guidelines of care for the management of cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol., 2018, 78(3), 560-578. doi: 10.1016/j.jaad.2017.10.007 PMID: 29331386
  6. Aasi, S.Z.; Hong, A.M. Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC). Available from: https://www.uptodate.com/contents/treatment-and-prognosis-of-low-risk-cutaneous-squamous-cell-carcinoma-cscc?sectionName=HIGH-RISK%20LESIONS&topicRef=13708&anchor=H4084930639&source=see_link#H4233402051
  7. Mazzoni, D.; Muir, J. A guide to curettage and cautery in the management of skin lesions. Aust. J. Gen. Pract., 2021, 50(12), 893-897. doi: 10.31128/AJGP-10-20-5695 PMID: 34845465
  8. Squamous Cell Carcinoma Treatment The Skin Cancer Foundation., 2022. Available from: https://www.skincancer.org/skin-cancer-information/squamous-cell-carcinoma/scc-treatment-options/
  9. DeSimone, J.A.; Hong, A.M. Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma. Available from: https://www.uptodate.com/contents/recognition-and-management-of-high-risk-aggressive-cutaneous-squamous-cell-carcinoma?topicRef=13708&source=see_link#H1262413
  10. Waldman, A.; Schmults, C. Cutaneous squamous cell carcinoma. Hematol. Oncol. Clin. North Am., 2019, 33(1), 1-12. doi: 10.1016/j.hoc.2018.08.001 PMID: 30497667
  11. Bertino, G.; Groselj, A.; Campana, L.G. Electrochemotherapy for the treatment of cutaneous squamous cell carcinoma: The INSPECT experience (2008-2020). Front. Oncol., 2020, 12, 951662. doi: 10.3389/fonc.2022.951662 PMID: 36203425
  12. LIBTAYO® (cemiplimab-rwlc) injection prescribing information: Regeneron Pharmaceuticals, Inc; 2018, 2018 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf
  13. Martins, G.R. Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies., Available from: https://www.uptodate.com/contents/systemic-treatment-of-advanced-basal-cell-and-cutaneous-squamous-cell-carcinomas-not-amenable-to-local-therapies?search=Smile%20fitness%20pants-Smile%20fitness%20pants%F0%9F%91%89Whatsapp%5BID%2018767976533%5Dgym%20pants%20manufacturer-fitness%20pants%20wholesalel0uBZ&topicRef=5339&source=see_link#H3398682241
  14. Schauder, D.M.; Kim, J.; Nijhawan, R.I. Evaluation of the use of capecitabine for the treatment and prevention of actinic keratoses, squamous cell carcinoma, and basal cell carcinoma. JAMA Dermatol., 2020, 156(10), 1117-1124. doi: 10.1001/jamadermatol.2020.2327 PMID: 32639538
  15. Li, J.Y.; Kampp, J.T. Review of common alternative herbal "remedies" for skin cancer. Dermatol. Surg., 2019, 45(1), 58-67. doi: 10.1097/DSS.0000000000001622 PMID: 30096105
  16. Prickett, K.A.; Ramsey, M.L. Mohs micrographic surgery. In: StatPearls; StatPearls Publishing: Treasure Island, FL, 2023.
  17. Fravor, L.; Khachemoune, A. Dermatologic uses of bloodroot: A review and reappraisal. Int. J. Dermatol., 2021, 60(9), 1070-1075. doi: 10.1111/ijd.15273 PMID: 33128472
  18. Croaker, A.; Liu, L.; Myers, S.P. Persisting cancer in black salve treated skin lesions: Results of a large 5 year retrospective analysis of australian histopathology specimens. Integr. Cancer Ther., 2023, 22. doi: 10.1177/15347354221151145 PMID: 36718525
  19. Wölfle, U.; Seelinger, G.; Schempp, C. Topical application of St. John’s wort (Hypericum perforatum). Planta Med., 2013, 80(02/03), 109-120. doi: 10.1055/s-0033-1351019 PMID: 24214835
  20. Alecu, M.; Ursaciuc, C.; Hãlãlãu, F.; Coman, G.; Merlevede, W.; Waelkens, E.; de Witte, P. Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin. Anticancer Res., 1998, 18(6B), 4651-4654. PMID: 9891535
  21. Kacerovská, D.; Pizinger, K.; Majer, F.; Šmíd, F. Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract--a pilot study. Photochem. Photobiol., 2008, 84(3), 779-785. doi: 10.1111/j.1751-1097.2007.00260.x PMID: 18179625
  22. Leskur, D.; Perišić, I.; Romac, K.; Šušak, H.; Šešelja, P.A.; Bukić, J.; Rušić, D.; Kladar, N.; Božin, B.; Modun, D. Comparison of mechanical, chemical and physical human models of in vivo skin damage: Randomized controlled trial. Skin Res. Technol., 2021, 27(2), 208-216. doi: 10.1111/srt.12932 PMID: 32686217
  23. Goldberg, L.H.; Landau, J.M.; Moody, M.N.; Vergilis-Kalner, I.J. Treatment of Bowen’s disease on the penis with low concentration of a standard mixture of solasodine glycosides and liquid nitrogen. Dermatol. Surg., 2011, 37(6), 858-861. doi: 10.1111/j.1524-4725.2011.02014.x PMID: 21605251
  24. Cham, B.E.; Daunter, B.; Evans, R.A. Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cancer Lett., 1991, 59(3), 183-192. doi: 10.1016/0304-3835(91)90140-D PMID: 1913614
  25. Greenberg, E.R.; Baron, J.A.; Stukel, T.A.; Stevens, M.M.; Mandel, J.S.; Spencer, S.K.; Elias, P.M.; Lowe, N.; Nierenberg, D.W.; Bayrd, G.; Vance, J.C.; Freeman, D.H., Jr; Clendenning, W.E.; Kwan, T. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. N. Engl. J. Med., 1990, 323(12), 789-795. doi: 10.1056/NEJM199009203231204 PMID: 2202901
  26. Laborada, J.; Cohen, P.R. Cutaneous squamous cell carcinoma and lichen simplex chronicus successfully treated with topical cannabinoid oil: A case report and summary of cannabinoids in dermatology. Cureus, 2022, 14(4), e23850. doi: 10.7759/cureus.23850
  27. Kumar, R.; Deep, G.; Agarwal, R. An overview of ultraviolet B radiation-induced skin cancer chemoprevention by silibinin. Curr. Pharmacol. Rep., 2015, 1(3), 206-215. doi: 10.1007/s40495-015-0027-9 PMID: 26097804
  28. Tilley, C.; Deep, G.; Agarwal, C.; Wempe, M.F.; Biedermann, D.; Valentová, K.; Kren, V.; Agarwal, R. Silibinin and its 2,3‐dehydro‐derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation. Mol. Carcinog., 2016, 55(1), 3-14. doi: 10.1002/mc.22253 PMID: 25492239
  29. Prasad, R.R.; Paudel, S.; Raina, K.; Agarwal, R. Silibinin and non-melanoma skin cancers. J. Tradit. Complement. Med., 2020, 10(3), 236-244. doi: 10.1016/j.jtcme.2020.02.003
  30. Dhanalakshmi, S.; Mallikarjuna, G.U.; Singh, R.P.; Agarwal, R. Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis, 2004, 25(8), 1459-1465. doi: 10.1093/carcin/bgh152 PMID: 15033902
  31. Gu, M.; Dhanalakshmi, S.; Singh, R.P.; Agarwal, R. Dietary feeding of silibinin prevents early biomarkers of UVB radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis. Cancer Epidemiol. Biomarkers Prev., 2005, 14(5), 1344-1349. doi: 10.1158/1055-9965.EPI-04-0664 PMID: 15894701
  32. Hoh, C.; Boocock, D.; Marczylo, T.; Singh, R.; Berry, D.P.; Dennison, A.R.; Hemingway, D.; Miller, A.; West, K.; Euden, S.; Garcea, G.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: Silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin. Cancer Res., 2006, 12(9), 2944-2950. doi: 10.1158/1078-0432.CCR-05-2724 PMID: 16675592
  33. Flaig, T.W.; Glodé, M.; Gustafson, D.; van Bokhoven, A.; Tao, Y.; Wilson, S.; Su, L.J.; Li, Y.; Harrison, G.; Agarwal, R.; Crawford, E.D.; Lucia, M.S.; Pollak, M. A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate, 2010, 70(8), 848-855. doi: 10.1002/pros.21118 PMID: 20127732
  34. Wei, H.; Bowen, R.; Zhang, X.; Lebwohl, M. Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice. Carcinogenesis, 1998, 19(8), 1509-1514. doi: 10.1093/carcin/19.8.1509 PMID: 9744550
  35. Pawlicka, M.; Filip, A. Can genistein be a potential agent against skin side effects associated with the treatment of breast cancer? Postepy Dermatol. Alergol., 2022, 39(1), 7-12. doi: 10.5114/ada.2022.113800 PMID: 35369627
  36. Isoherranen, K.; Punnonen, K.; Jansen, C.; Uotila, P. Ultraviolet irradiation induces cyclooxygenase-2 expression in keratinocytes. Br. J. Dermatol., 1999, 140(6), 1017-1022. doi: 10.1046/j.1365-2133.1999.02897.x PMID: 10354065
  37. Iovine, B.; Iannella, M.L.; Gasparri, F.; Monfrecola, G.; Bevilacqua, M.A. Synergic effect of genistein and daidzein on UVB-induced DNA damage: An effective photoprotective combination. J. Biomed. Biotechnol., 2011, 2011, 1-8. doi: 10.1155/2011/692846 PMID: 21785564
  38. Wang, Y.N.; Wu, W.; Chen, H.C.; Fang, H. Genistein protects against UVB-induced senescence-like characteristics in human dermal fibroblast by p66Shc down-regulation. J. Dermatol. Sci., 2010, 58(1), 19-27. doi: 10.1016/j.jdermsci.2010.02.002 PMID: 20211546
  39. Zhang, Y.; Ai, P.; Chen, S.; Lei, S. Sulforaphane suppresses skin squamous cell carcinoma cells proliferation through miR-199a-5p/Sirt1/CD44ICD signaling pathway. Immunopharmacol. Immunotoxicol., 2023, 45(1), 52-60. doi: 10.1080/08923973.2022.2112221 PMID: 35947042
  40. Alyoussef, A.; Taha, M. Antitumor activity of sulforaphane in mice model of skin cancer via blocking sulfatase‐2. Exp. Dermatol., 2019, 28(1), 28-34. doi: 10.1111/exd.13802 PMID: 30315662
  41. Dickinson, S.E.; Rusche, J.J.; Bec, S.L.; Horn, D.J.; Janda, J.; Rim, S.H.; Smith, C.L.; Bowden, G.T. The effect of sulforaphane on histone deacetylase activity in keratinocytes: Differences between in vitro and in vivo analyses. Mol. Carcinog., 2015, 54(11), 1513-1520. doi: 10.1002/mc.22224 PMID: 25307283
  42. Afaq, F. Natural agents: Cellular and molecular mechanisms of photoprotection. Arch. Biochem. Biophys., 2011, 508(2), 144-151. doi: 10.1016/j.abb.2010.12.007 PMID: 21147060
  43. Mazière, C.; Dantin, F.; Dubois, F.; Santus, R.; Mazière, J.C. Biphasic effect of UVA radiation on STAT1 activity and tyrosine phosphorylation in cultured human keratinocytes. Free Radic. Biol. Med., 2000, 28(9), 1430-1437. doi: 10.1016/S0891-5849(00)00264-1 PMID: 10924861
  44. Wang, Y.; Zhang, X.; Lebwohl, M.; DeLeo, V.; Wei, H. Inhibition of ultraviolet B (UVB)-induced c-fos and c-jun expression in vivo by a tyrosine kinase inhibitor genistein. Carcinogenesis, 1998, 19(4), 649-654. doi: 10.1093/carcin/19.4.649 PMID: 9600350
  45. Stratton, S.P.; Alberts, D.S.; Einspahr, J.G.; Sagerman, P.M.; Warneke, J.A.; Curiel-Lewandrowski, C.; Myrdal, P.B.; Karlage, K.L.; Nickoloff, B.J.; Brooks, C.; Saboda, K.; Yozwiak, M.L.; Krutzsch, M.F.; Hu, C.; Lluria-Prevatt, M.; Dong, Z.; Bowden, G.T.; Bartels, P.H. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. Cancer Prev. Res., 2010, 3(2), 160-169. doi: 10.1158/1940-6207.CAPR-09-0183 PMID: 20103724
  46. Mentor, JM; Etemadi, A; Patta, AM; Scheinfeld, N Topical AC-11 abates actinic keratoses and early squamous cell cancers in hairless mice exposed to Ultraviolet A (UVA) radiation. Dermatol Online J., 2015, 21(4), 13030/qt5rt46141.
  47. Yang, S.Y.; Wang, H.M.; Wu, T.W.; Chen, Y.J.; Shieh, J.J.; Lin, J.H.; Ho, T.F.; Luo, R.J.; Chen, C.Y.; Chang, C.C. Subamolide B isolated from medicinal plant cinnamomum subavenium induces cytotoxicity in human cutaneous squamous cell carcinoma cells through mitochondrial and CHOP-dependent cell death pathways. Evid. Based Complement. Alternat. Med., 2013, 2013, 1-13. doi: 10.1155/2013/630415 PMID: 23573140
  48. Chen, C.Y.; Chen, C.H.; Wong, C.H.; Liu, Y.W.; Lin, Y.S.; Wang, Y.D.; Hsui, Y.R. Cytotoxic constituents of the stems of Cinnamomum subavenium. J. Nat. Prod., 2007, 70(1), 103-106. doi: 10.1021/np060425k PMID: 17253858
  49. Duncan, F.J.; Martin, J.R.; Wulff, B.C.; Stoner, G.D.; Tober, K.L.; Oberyszyn, T.M.; Kusewitt, D.F.; Van Buskirk, A.M. Topical treatment with black raspberry extract reduces cutaneous UVB-induced carcinogenesis and inflammation. Cancer Prev. Res., 2009, 2(7), 665-672. doi: 10.1158/1940-6207.CAPR-08-0193 PMID: 19584078
  50. Zhao, J.; Wang, J.; Chen, Y.; Agarwal, R. Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation–promotion protocol and identification of procyanidin B5-3′-gallate as the most effective antioxidant constituent. Carcinogenesis, 1999, 20(9), 1737-1745. doi: 10.1093/carcin/20.9.1737 PMID: 10469619
  51. Meeran, S.M.; Katiyar, S.K. Proanthocyanidins inhibit mitogenic and survival-signaling in vitro and tumor growth in vivo. Front. Biosci., 2008, 13, 887-897. doi: 10.2741/2729
  52. Lee, Y. Cancer chemopreventive potential of procyanidin. Toxicol. Res., 2017, 33(4), 273-282. doi: 10.5487/TR.2017.33.4.273 PMID: 29071011
  53. Sonavane, K.; Phillips, J.; Ekshyyan, O.; Moore-Medlin, T.; Roberts Gill, J.; Rong, X.; Lakshmaiah, R.R.; Abreo, F.; Boudreaux, D.; Clifford, J.L.; Nathan, C.A.O. Topical curcumin-based cream is equivalent to dietary curcumin in a skin cancer model. J. Skin Cancer, 2012, 2012, 1-9. doi: 10.1155/2012/147863 PMID: 23316365
  54. Vollono, L.; Falconi, M.; Gaziano, R. Potential of curcumin in skin disorders. Nutrients, 2019, 11(9), 2169. doi: 10.3390/nu11092169
  55. Kuttan, R.; Sudheeran, P.C.; Josph, C.D. Turmeric and curcumin as topical agents in cancer therapy. Tumori, 1987, 73(1), 29-31. doi: 10.1177/030089168707300105 PMID: 2435036
  56. Cheng, A.L.; Hsu, C.H.; Lin, J.K.; Hsu, M.M.; Ho, Y.F.; Shen, T.S.; Ko, J.Y.; Lin, J.T.; Lin, B.R.; Ming-Shiang, W.; Yu, H.S.; Jee, S.H.; Chen, G.S.; Chen, T.M.; Chen, C.A.; Lai, M.K.; Pu, Y.S.; Pan, M.H.; Wang, Y.J.; Tsai, C.C.; Hsieh, C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 2001, 21(4B), 2895-2900. PMID: 11712783
  57. Kim, J.K.; Kim, Y.; Na, K.M.; Surh, Y.J.; Kim, T.Y. 6-Gingerol prevents UVB-induced ROS production and COX-2 expression in vitro and in vivo. Free Radic. Res., 2007, 41(5), 603-614. doi: 10.1080/10715760701209896 PMID: 17454143
  58. Katiyar, S.K.; Agarwal, R.; Mukhtar, H. Inhibition of tumor promotion in SENCAR mouse skin by ethanol extract of Zingiber officinale rhizome. Cancer Res., 1996, 56(5), 1023-1030. PMID: 8640756
  59. Nigam, N.; Bhui, K.; Prasad, S.; George, J.; Shukla, Y. 6-Gingerol induces reactive oxygen species regulated mitochondrial cell death pathway in human epidermoid carcinoma A431 cells. Chem. Biol. Interact., 2009, 181(1), 77-84. doi: 10.1016/j.cbi.2009.05.012 PMID: 19481070
  60. Kessels, J.; Voeten, L.; Nelemans, P.; Cleutjens, J.; Hillen, L.M.; Mosterd, K.; Kelleners-Smeets, N.W.J. Topical sinecatechins, 10%, ointment for superficial basal cell carcinoma. JAMA Dermatol., 2017, 153(10), 1061-1063. doi: 10.1001/jamadermatol.2017.2529 PMID: 28793140
  61. Asgari, M.; White, E.; Warton, E.M.; Hararah, M.; Friedman, G.; Chren, M.M. Association of tea consumption and cutaneous squamous cell carcinoma. Nutr. Cancer, 2011, 63(2), 314-318. doi: 10.1080/01635581.2011.523496 PMID: 21240832
  62. Rees, J.R.; Stukel, T.A.; Perry, A.E.; Zens, M.S.; Spencer, S.K.; Karagas, M.R. Tea consumption and basal cell and squamous cell skin cancer: Results of a case-control study. J. Am. Acad. Dermatol., 2007, 56(5), 781-785. doi: 10.1016/j.jaad.2006.11.038 PMID: 17261341
  63. Hakim, I.A.; Harris, R.B. Joint effects of citrus peel use and black tea intake on the risk of squamous cell carcinoma of the skin. BMC Dermatol., 2001, 1(1), 3. doi: 10.1186/1471-5945-1-3 PMID: 11527506
  64. Hakim, I.A.; Harris, R.B.; Weisgerber, U.M. Tea intake and squamous cell carcinoma of the skin: Influence of type of tea beverages. Cancer Epidemiol. Biomarkers Prev., 2000, 9(7), 727-731. PMID: 10919744
  65. Filip, A.; Clichici, S.; Daicoviciu, D.; Catoi, C.; Bolfa, P.; Postescu, I.D.; Gal, A.; Baldea, I.; Gherman, C.; Muresan, A. Chemopreventive effects of Calluna vulgaris and Vitis vinifera extracts on UVB-induced skin damage in SKH-1 hairless mice. J. Physiol. Pharmacol., 2011, 62(3), 385-392. PMID: 21893700
  66. Oak, A.S.W.; Shafi, R.; Elsayed, M.; Mishra, B.; Bae, S.; Barnes, S.; Kashyap, M.P.; Slominski, A.T.; Wilson, L.S.; Athar, M.; Elmets, C.A. Dietary table grape protects against ultraviolet photodamage in humans: 2. molecular biomarker studies. J. Am. Acad. Dermatol., 2021, 85(4), 1032-1034. doi: 10.1016/j.jaad.2021.01.036 PMID: 33484768
  67. Oak, A.S.W.; Shafi, R.; Elsayed, M.; Bae, S.; Saag, L.; Wang, C.L.; Athar, M.; Elmets, C.A. Dietary table grape protects against ultraviolet photodamage in humans: 1. clinical evaluation. J. Am. Acad. Dermatol., 2021, 85(4), 1030-1032. doi: 10.1016/j.jaad.2021.01.035 PMID: 33484767
  68. Rizwan, M.; Rodriguez-Blanco, I.; Harbottle, A.; Birch-Machin, M.A.; Watson, R.E.B.; Rhodes, L.E. Tomato paste rich in lycopene protects against cutaneous photodamage in humans in vivo: A randomized controlled trial. Br. J. Dermatol., 2011, 164(1), 154-162. doi: 10.1111/j.1365-2133.2010.10057.x PMID: 20854436
  69. Ramsay, J.R.; Suhrbier, A.; Aylward, J.H.; Ogbourne, S.; Cozzi, S.J.; Poulsen, M.G.; Baumann, K.C.; Welburn, P.; Redlich, G.L.; Parsons, P.G. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br. J. Dermatol., 2011, 164(3) no. doi: 10.1111/j.1365-2133.2010.10184.x PMID: 21375515
  70. PICATO® (ingenol mebutate) gel, 0.015% for topical use PICATO ® (ingenol mebutate) gel, 0.05% for topical use, LEO Pharma Inc. 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202833lbl.pdf
  71. Ahmady, S.; Jansen, M.H.E.; Nelemans, P.J.; Kessels, J.P.H.M.; Arits, A.H.M.M.; de Rooij, M.J.M.; Essers, B.A.B.; Quaedvlieg, P.J.F.; Kelleners-Smeets, N.W.J.; Mosterd, K. Risk of invasive cutaneous squamous cell carcinoma after different treatments for actinic keratosis. JAMA Dermatol., 2022, 158(6), 634-640. doi: 10.1001/jamadermatol.2022.1034 PMID: 35475852
  72. PICATO® (ingenol mebutate) gel, 0.015% for topical use PICATO ® (ingenol mebutate) gel, 0.05% for topical use, LEO Pharma Inc; 2012, 2012 Available from: https://www.accessdata.fda. gov/drugsatfda_docs/label/2012/202833lbl.pdf
  73. Khalfe, Y.; Rosen, T. Ingenol mebutate as treatment of squamous cell carcinoma in situ: A case series. J. Drugs Dermatol., 2021, 20(2), 169-171. doi: 10.36849/JDD.5602 PMID: 33538561
  74. SOLARAZE® GEL. 2011. Available from: https://www. accessdata.fda.gov/drugsatfda_docs/label/2011/021005s013lbl.pdf
  75. Pentland, A.P.; Schoggins, J.W.; Scott, G.A.; Khan, K.N.M.; Han, R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis, 1999, 20(10), 1939-1944. doi: 10.1093/carcin/20.10.1939 PMID: 10506108
  76. Asgari, M.; White, E.; Chren, M.M. Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma. Dermatol. Surg., 2004, 30(10), 1335-1342. doi: 10.1111/j.1524-4725.2004.30407.x PMID: 15458531
  77. Dawe, S.A.; Salisbury, J.R.; Higgins, E. Two cases of Bowen’s disease successfully treated topically with 3% diclofenac in 2.5% hyaluronan gel. Clin. Exp. Dermatol., 2005, 30(6), 712-713. doi: 10.1111/j.1365-2230.2005.01867.x PMID: 16197397
  78. Jeter, J.M.; Curiel-Lewandrowski, C.; Stratton, S.P.; Myrdal, P.B.; Warneke, J.A.; Einspahr, J.G.; Bartels, H.G.; Yozwiak, M.; Bermudez, Y.; Hu, C.; Bartels, P.; Alberts, D.S. Phase IIB randomized study of topical difluoromethylornithine and topical diclofenac on sun-damaged skin of the forearm. Cancer Prev. Res., 2016, 9(2), 128-134. doi: 10.1158/1940-6207.CAPR-15-0232 PMID: 26712942
  79. Bailey, H.H.; Kim, K.; Verma, A.K.; Sielaff, K.; Larson, P.O.; Snow, S.; Lenaghan, T.; Viner, J.L.; Douglas, J.; Dreckschmidt, N.E.; Hamielec, M.; Pomplun, M.; Sharata, H.H.; Puchalsky, D.; Berg, E.R.; Havighurst, T.C.; Carbone, P.P. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of alpha-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev. Res., 2010, 3(1), 35-47. doi: 10.1158/1940-6207.CAPR-09-0096 PMID: 20051371
  80. Carbone, P.P.; Pirsch, J.D.; Thomas, J.P.; Douglas, J.A.; Verma, A.K.; Larson, P.O.; Snow, S.; Tutsch, K.D.; Pauk, D. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. Cancer Epidemiol. Biomarkers Prev., 2001, 10(6), 657-661. PMID: 11401916
  81. Kilgour, J.M.; Shah, A.; Eichstadt, S.; Bailey, I.; Aasi, S.Z.; Sarin, K.Y. Treatment of cutaneous squamous cell carcinoma with the topical histone deacetylase inhibitor remetinostat. JAMA Dermatol., 2022, 158(1), 105-107. doi: 10.1001/jamadermatol.2021.4549 PMID: 34787644
  82. Kalin, J.H.; Eroglu, A.; Liu, H. Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model. PLoS One, 2019, 14(3), e0213095. doi: 10.1371/journal.pone.0213095
  83. Chen, A.C.; Martin, A.J.; Choy, B.; Fernández-Peñas, P.; Dalziell, R.A.; McKenzie, C.A.; Scolyer, R.A.; Dhillon, H.M.; Vardy, J.L.; Kricker, A.; St George, G.; Chinniah, N.; Halliday, G.M.; Damian, D.L. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N. Engl. J. Med., 2015, 373(17), 1618-1626. doi: 10.1056/NEJMoa1506197 PMID: 26488693
  84. Mainville, L.; Smilga, A.S.; Fortin, P.R. Effect of nicotinamide in skin cancer and actinic keratoses chemoprophylaxis, and adverse effects related to nicotinamide: A systematic review and meta-analysis. J. Cutan. Med. Surg., 2022, 26(3), 297-308. doi: 10.1177/12034754221078201 PMID: 35134311
  85. Allen, N.C.; Martin, A.J.; Snaidr, V.A.; Eggins, R.; Chong, A.H.; Fernandéz-Peñas, P.; Gin, D.; Sidhu, S.; Paddon, V.L.; Banney, L.A.; Lim, A.; Upjohn, E.; Schaider, H.; Ganhewa, A.D.; Nguyen, J.; McKenzie, C.A.; Prakash, S.; McLean, C.; Lochhead, A.; Ibbetson, J.; Dettrick, A.; Landgren, A.; Allnutt, K.J.; Allison, C.; Davenport, R.B.; Mumford, B.P.; Wong, B.; Stagg, B.; Tedman, A.; Gribbin, H.; Edwards, H.A.; De Rosa, N.; Stewart, T.; Doolan, B.J.; Kok, Y.; Simpson, K.; Low, Z.M.; Kovitwanichkanont, T.; Scolyer, R.A.; Dhillon, H.M.; Vardy, J.L.; Chadban, S.J.; Bowen, D.G.; Chen, A.C.; Damian, D.L. Nicotinamide for skin-cancer chemoprevention in transplant recipients. N. Engl. J. Med., 2023, 388(9), 804-812. doi: 10.1056/NEJMoa2203086 PMID: 36856616
  86. Lin, X.Y.; He, C.D.; Xiao, T.; Jin, X.; Chen, J.; Wang, Y.K.; Liu, M.; Wang, K.B.; Jiang, Y.; Wei, H.C.; Chen, H.D. Acitretin induces apoptosis through CD95 signalling pathway in human cutaneous squamous cell carcinoma cell line SCL‐1. J. Cell. Mol. Med., 2009, 13(9a), 2888-2898. doi: 10.1111/j.1582-4934.2008.00397.x PMID: 18624760
  87. Wang, H.; Bata, B.; Currie, Z.; Salvi, S.; Tan, J. Systemic acitretin in the management of periocular squamous cell carcinoma. BMJ Case Rep., 2021, 14(4), e241167. doi: 10.1136/bcr-2020-241167
  88. Kadakia, K.C.; Barton, D.L.; Loprinzi, C.L.; Sloan, J.A.; Otley, C.C.; Diekmann, B.B.; Novotny, P.J.; Alberts, S.R.; Limburg, P.J.; Pittelkow, M.R. Randomized controlled trial of acitretin versus placebo in patients at high‐risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer, 2012, 118(8), 2128-2137. doi: 10.1002/cncr.26374 PMID: 21882176
  89. Martin-Gorgojo, A.; Gilaberte, Y.; Nagore, E. Vitamin D and skin cancer: An epidemiological, patient-centered update and review. Nutrients, 2021, 13(12), 4292. doi: 10.3390/nu13124292
  90. Anand, S.; Rollakanti, K.R.; Horst, R.L.; Hasan, T.; Maytin, E.V. Combination of oral vitamin D3 with photodynamic therapy enhances tumor cell death in a murine model of cutaneous squamous cell carcinoma. Photochem. Photobiol., 2014, 90(5), 1126-1135. doi: 10.1111/php.12286 PMID: 24807677
  91. Curiel-Lewandrowski, C.; Tang, J.Y.; Einspahr, J.G.; Bermudez, Y.; Hsu, C.H.; Rezaee, M.; Lee, A.H.; Tangrea, J.; Parnes, H.L.; Alberts, D.S.; Chow, H.H.S. Pilot study on the bioactivity of vitamin d in the skin after oral supplementation. Cancer Prev. Res., 2015, 8(6), 563-569. doi: 10.1158/1940-6207.CAPR-14-0280 PMID: 25835512
  92. Gade, A.; Hwang, J.R.; Hoegler, K.; Khan, S.; Khachemoune, A. Therapeutic use of trace elements in dermatology. Altern. Ther. Health Med., 2023, 29(4), 246-252. PMID: 34264859
  93. Clark, L.C.; Combs, G.F., Jr; Turnbull, B.W.; Slate, E.H.; Chalker, D.K.; Chow, J.; Davis, L.S.; Glover, R.A.; Graham, G.F.; Gross, E.G.; Krongrad, A.; Lesher, J.L., Jr; Park, H.K.; Sanders, B.B., Jr; Smith, C.L.; Taylor, J.R. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. JAMA, 1996, 276(24), 1957-1963. doi: 10.1001/jama.1996.03540240035027 PMID: 8971064
  94. Argos, M.; Dignam, J.J.; Parvez, F.; Rahman, M.; Hore, S.K.; Shahriar, M.H.; Sarwar, G.; Islam, T.; Slavkovich, V.; Graziano, J.; Gamble, M.; Harjes, J.; Anton, K.; Kibriya, M.G.; Jasmine, F.; Kamal, M.; Shea, C.R.; Yunus, M.; Baron, J.A.; Ahsan, H. A randomized trial of selenium and vitamin E for primary prevention of non-melanoma skin cancer: Trial results and experience from a low-resource setting. J. Clin. Oncol., 2017, 35(S15), 1511. doi: 10.1200/JCO.2017.35.15_suppl.1511
  95. Caini, S.; Cattaruzza, S.; Bendinelli, B.; Tosti, G.; Masala, G.; Gnagnarella, P.; Assedi, M.; Stanganelli, I.; Palli, D.; Gandini, S. Coffee, tea and caffeine intake and the risk of non-melanoma skin cancer: A review of the literature and meta-analysis. Eur. J. Nutr., 2017, 56(1), 1-12. doi: 10.1007/s00394-016-1253-6 PMID: 27388462
  96. Zhang, X.; Bommareddy, A.; Chen, W. Chemopreventive effects of sarcophine-diol on ultraviolet B-induced skin tumor development in SKH-1 hairless mice. Mar. Drugs, 2009, 7(2), 153-165. doi: 10.3390/md7020153
  97. Kundoor, V.; Zhang, X.; Khalifa, S.; Fahmy, H.; Dwivedi, C. A possible mechanism of action of the chemopreventive effects of sarcotriol on skin tumor development in CD-1 mice. Mar. Drugs, 2006, 4(4), 274-285. doi: 10.3390/md404274
  98. Zhang, X.; Kundoor, V.; Khalifa, S.; Zeman, D.; Fahmy, H.; Dwivedi, C. Chemopreventive effects of sarcophine-diol on skin tumor development in CD-1 mice. Cancer Lett., 2007, 253(1), 53-59. doi: 10.1016/j.canlet.2007.01.009 PMID: 17321042
  99. Guillermo, R.F.; Zhang, X.; Kaushik, R.S.; Zeman, D.; Ahmed, S.A.; Khalifa, S.; Fahmy, H.; Dwivedi, C. Dose-response on the chemopreventive effects of sarcophine-diol on UVB-induced skin tumor development in SKH-1 hairless mice. Mar. Drugs, 2012, 10(12), 2111-2125. doi: 10.3390/md10092111 PMID: 23118725
  100. Mahen, K.K.; Markley, L.; Bogart, J.; Klatka, H.; Krishna, V.; Maytin, E.V.; Stark, G.R.; McDonald, C. Topical N ‐phosphonacetyl‐ L ‐aspartate is a dual action candidate for treating non‐melanoma skin cancer. Exp. Dermatol., 2023, 32(9), 1485-1497. doi: 10.1111/exd.14853 PMID: 37309615

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers